APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Onychomycosis (Tinea Unguium) Drug

Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate.

Onychomycosis (Tinea Unguium) Drug is the drug for the treatment of the disease.

Selected research

Market Analysis & Forecast

Global Onychomycosis (Tinea Unguium) Drug Market Analysis and Forecast 2026-2032

Report ID 174019070222 December 2025199 pages

Choose your research edition.

Industry ResearchOnychomycosis (Tinea Unguium) Drug Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Onychomycosis (Tinea Unguium) Drug Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Onychomycosis (Tinea Unguium) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Onychomycosis (Tinea Unguium) Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Onychomycosis (Tinea Unguium) Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate.

Onychomycosis (Tinea Unguium) Drug is the drug for the treatment of the disease.

Global Onychomycosis (Tinea Unguium) Drug key players include Pfizer, J&J, Novartis, Galderma pharm, Valeant Pharma, etc. Global top five manufacturers hold a share about 35%.

Read the full market overview

North America is the largest market, with a share about 30%, followed by Europe and China both have a share over 45 percent.

In terms of product, Oral Medication is the largest segment, with a share over 70%. And in terms of application, the largest application is Age above 50, followed by Age under 18.

Report Includes

This report presents an overview of global market for Onychomycosis (Tinea Unguium) Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Onychomycosis (Tinea Unguium) Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Onychomycosis (Tinea Unguium) Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Onychomycosis (Tinea Unguium) Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Onychomycosis (Tinea Unguium) Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Onychomycosis (Tinea Unguium) Drug revenue, projected growth trends, production technology, application and end-user industry.

Onychomycosis (Tinea Unguium) Drug Segment by Company

Pfizer

Yangtze River

Torrent Pharma

J&J

Chengdu Brilliant

Novartis

Qilu Pharmaceutical

Xiuzheng Pharmaceutical

Hubei Hengan

TARO

Perrigo

Galderma pharm

Zhejiang Deyer

Valeant Pharma

Moberg

Onychomycosis (Tinea Unguium) Drug Segment by Type

Oral Medication

External Medicine

Onychomycosis (Tinea Unguium) Drug Segment by Application

Age under 18

Age 18-50

Age above 50

Onychomycosis (Tinea Unguium) Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Onychomycosis (Tinea Unguium) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Onychomycosis (Tinea Unguium) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Onychomycosis (Tinea Unguium) Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Onychomycosis (Tinea Unguium) Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Onychomycosis (Tinea Unguium) Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Onychomycosis (Tinea Unguium) Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Onychomycosis (Tinea Unguium) Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oral Medication Major Player Table 3. External Medicine Major Player Table 4. Global Onychomycosis (Tinea Unguium) Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Age under 18 Major Player Table 6. Age 18-50 Major Player Table 7. Age above 50 Major Player Table 8. Onychomycosis (Tinea Unguium) Drug Industry Trends Table 9. Onychomycosis (Tinea Unguium) Drug Industry Drivers Table 10. Onychomycosis (Tinea Unguium) Drug Industry Opportunities and Challenges Table 11. Onychomycosis (Tinea Unguium) Drug Industry Restraints Table 12. Global Onychomycosis (Tinea Unguium) Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Onychomycosis (Tinea Unguium) Drug Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Onychomycosis (Tinea Unguium) Drug Market Share by Region (2021-2026) Table 15. Global Onychomycosis (Tinea Unguium) Drug Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Onychomycosis (Tinea Unguium) Drug Market Share by Region (2027-2032) Table 17. Global Onychomycosis (Tinea Unguium) Drug Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Players (2021-2026) Table 19. Global Onychomycosis (Tinea Unguium) Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Onychomycosis (Tinea Unguium) Drug Key Players Headquarters & Area Served Table 21. Global Onychomycosis (Tinea Unguium) Drug Players, Product Type & Application Table 22. Global Onychomycosis (Tinea Unguium) Drug Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Onychomycosis (Tinea Unguium) Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Onychomycosis (Tinea Unguium) Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Onychomycosis (Tinea Unguium) Drug Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Onychomycosis (Tinea Unguium) Drug Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Type (2021-2026) Table 29. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Type (2027-2032) Table 30. Global Onychomycosis (Tinea Unguium) Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Onychomycosis (Tinea Unguium) Drug Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Onychomycosis (Tinea Unguium) Drug Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Application (2021-2026) Table 34. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Application (2027-2032) Table 35. Pfizer Company Information Table 36. Pfizer Business Overview Table 37. Pfizer Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Pfizer Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 39. Pfizer Recent Development Table 40. Yangtze River Company Information Table 41. Yangtze River Business Overview Table 42. Yangtze River Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Yangtze River Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 44. Yangtze River Recent Development Table 45. Torrent Pharma Company Information Table 46. Torrent Pharma Business Overview Table 47. Torrent Pharma Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Torrent Pharma Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 49. Torrent Pharma Recent Development Table 50. J&J Company Information Table 51. J&J Business Overview Table 52. J&J Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. J&J Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 54. J&J Recent Development Table 55. Chengdu Brilliant Company Information Table 56. Chengdu Brilliant Business Overview Table 57. Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 59. Chengdu Brilliant Recent Development Table 60. Novartis Company Information Table 61. Novartis Business Overview Table 62. Novartis Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Novartis Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 64. Novartis Recent Development Table 65. Qilu Pharmaceutical Company Information Table 66. Qilu Pharmaceutical Business Overview Table 67. Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 69. Qilu Pharmaceutical Recent Development Table 70. Xiuzheng Pharmaceutical Company Information Table 71. Xiuzheng Pharmaceutical Business Overview Table 72. Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 74. Xiuzheng Pharmaceutical Recent Development Table 75. Hubei Hengan Company Information Table 76. Hubei Hengan Business Overview Table 77. Hubei Hengan Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Hubei Hengan Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 79. Hubei Hengan Recent Development Table 80. TARO Company Information Table 81. TARO Business Overview Table 82. TARO Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. TARO Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 84. TARO Recent Development Table 85. Perrigo Company Information Table 86. Perrigo Business Overview Table 87. Perrigo Onychomycosis (Tinea Unguium) Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 88. Perrigo Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 89. Perrigo Recent Development Table 90. Galderma pharm Company Information Table 91. Galderma pharm Business Overview Table 92. Galderma pharm Onychomycosis (Tinea Unguium) Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Galderma pharm Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 94. Galderma pharm Recent Development Table 95. Zhejiang Deyer Company Information Table 96. Zhejiang Deyer Business Overview Table 97. Zhejiang Deyer Onychomycosis (Tinea Unguium) Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Zhejiang Deyer Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 99. Zhejiang Deyer Recent Development Table 100. Valeant Pharma Company Information Table 101. Valeant Pharma Business Overview Table 102. Valeant Pharma Onychomycosis (Tinea Unguium) Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Valeant Pharma Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 104. Valeant Pharma Recent Development Table 105. Moberg Company Information Table 106. Moberg Business Overview Table 107. Moberg Onychomycosis (Tinea Unguium) Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. Moberg Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 109. Moberg Recent Development Table 110. North America Onychomycosis (Tinea Unguium) Drug Revenue by Type (2021-2026) & (US$ Million) Table 111. North America Onychomycosis (Tinea Unguium) Drug Revenue by Type (2027-2032) & (US$ Million) Table 112. North America Onychomycosis (Tinea Unguium) Drug Revenue by Application (2021-2026) & (US$ Million) Table 113. North America Onychomycosis (Tinea Unguium) Drug Revenue by Application (2027-2032) & (US$ Million) Table 114. North America Onychomycosis (Tinea Unguium) Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. North America Onychomycosis (Tinea Unguium) Drug Revenue by Country (2021-2026) & (US$ Million) Table 116. North America Onychomycosis (Tinea Unguium) Drug Revenue by Country (US$ Million) & (2027-2032) Table 117. Europe Onychomycosis (Tinea Unguium) Drug Revenue by Type (2021-2026) & (US$ Million) Table 118. Europe Onychomycosis (Tinea Unguium) Drug Revenue by Type (2027-2032) & (US$ Million) Table 119. Europe Onychomycosis (Tinea Unguium) Drug Revenue by Application (2021-2026) & (US$ Million) Table 120. Europe Onychomycosis (Tinea Unguium) Drug Revenue by Application (2027-2032) & (US$ Million) Table 121. Europe Onychomycosis (Tinea Unguium) Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. Europe Onychomycosis (Tinea Unguium) Drug Revenue by Country (2021-2026) & (US$ Million) Table 123. Europe Onychomycosis (Tinea Unguium) Drug Revenue by Country (US$ Million) & (2027-2032) Table 124. China Onychomycosis (Tinea Unguium) Drug Revenue by Type (2021-2026) & (US$ Million) Table 125. China Onychomycosis (Tinea Unguium) Drug Revenue by Type (2027-2032) & (US$ Million) Table 126. China Onychomycosis (Tinea Unguium) Drug Revenue by Application (2021-2026) & (US$ Million) Table 127. China Onychomycosis (Tinea Unguium) Drug Revenue by Application (2027-2032) & (US$ Million) Table 128. Asia Onychomycosis (Tinea Unguium) Drug Revenue by Type (2021-2026) & (US$ Million) Table 129. Asia Onychomycosis (Tinea Unguium) Drug Revenue by Type (2027-2032) & (US$ Million) Table 130. Asia Onychomycosis (Tinea Unguium) Drug Revenue by Application (2021-2026) & (US$ Million) Table 131. Asia Onychomycosis (Tinea Unguium) Drug Revenue by Application (2027-2032) & (US$ Million) Table 132. Asia Onychomycosis (Tinea Unguium) Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 133. Asia Onychomycosis (Tinea Unguium) Drug Revenue by Region (US$ Million) & (2021-2026) Table 134. Asia Onychomycosis (Tinea Unguium) Drug Revenue by Region (US$ Million) & (2027-2032) Table 135. SAMEA Onychomycosis (Tinea Unguium) Drug Revenue by Type (2021-2026) & (US$ Million) Table 136. SAMEA Onychomycosis (Tinea Unguium) Drug Revenue by Type (2027-2032) & (US$ Million) Table 137. SAMEA Onychomycosis (Tinea Unguium) Drug Revenue by Application (2021-2026) & (US$ Million) Table 138. SAMEA Onychomycosis (Tinea Unguium) Drug Revenue by Application (2027-2032) & (US$ Million) Table 139. SAMEA Onychomycosis (Tinea Unguium) Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. SAMEA Onychomycosis (Tinea Unguium) Drug Revenue by Country (2021-2026) & (US$ Million) Table 141. SAMEA Onychomycosis (Tinea Unguium) Drug Revenue by Country (US$ Million) & (2027-2032) Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Onychomycosis (Tinea Unguium) Drug Image Figure 2. Global Onychomycosis (Tinea Unguium) Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Onychomycosis (Tinea Unguium) Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oral Medication Image Figure 5. External Medicine Image Figure 6. Global Onychomycosis (Tinea Unguium) Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Onychomycosis (Tinea Unguium) Drug Market Size Share 2021 VS 2025 VS 2032 Figure 8. Age under 18 Image Figure 9. Age 18-50 Image Figure 10. Age above 50 Image Figure 11. Global Onychomycosis (Tinea Unguium) Drug Market Size (US$ Million) & (2021-2032) Figure 12. Global Onychomycosis (Tinea Unguium) Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Onychomycosis (Tinea Unguium) Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Onychomycosis (Tinea Unguium) Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Onychomycosis (Tinea Unguium) Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Type (2021-2032) Figure 19. Global Onychomycosis (Tinea Unguium) Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Application (2021-2032) Figure 22. North America Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Onychomycosis (Tinea Unguium) Drug Revenue Share by Type (2021-2032) Figure 24. North America Onychomycosis (Tinea Unguium) Drug Revenue Share by Application (2021-2032) Figure 25. North America Onychomycosis (Tinea Unguium) Drug Revenue Share by Country (2021-2032) Figure 26. United States Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Onychomycosis (Tinea Unguium) Drug Revenue Share by Type (2021-2032) Figure 31. Europe Onychomycosis (Tinea Unguium) Drug Revenue Share by Application (2021-2032) Figure 32. Europe Onychomycosis (Tinea Unguium) Drug Revenue Share by Country (2021-2032) Figure 33. Germany Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Onychomycosis (Tinea Unguium) Drug Revenue Share by Type (2021-2032) Figure 43. China Onychomycosis (Tinea Unguium) Drug Revenue Share by Application (2021-2032) Figure 44. Asia Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Onychomycosis (Tinea Unguium) Drug Revenue Share by Type (2021-2032) Figure 46. Asia Onychomycosis (Tinea Unguium) Drug Revenue Share by Application (2021-2032) Figure 47. Asia Onychomycosis (Tinea Unguium) Drug Revenue Share by Region (2021-2032) Figure 48. Japan Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Onychomycosis (Tinea Unguium) Drug Revenue Share by Type (2021-2032) Figure 56. SAMEA Onychomycosis (Tinea Unguium) Drug Revenue Share by Application (2021-2032) Figure 57. SAMEA Onychomycosis (Tinea Unguium) Drug Revenue Share by Country (2021-2032) Figure 58. Brazil Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Onychomycosis (Tinea Unguium) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Medication
  • External Medicine
Applications
  • Age under 18
  • Age 18-50
  • Age above 50
Companies covered
  • Pfizer
  • Yangtze River
  • Torrent Pharma
  • J&J
  • Chengdu Brilliant
  • Novartis
  • Qilu Pharmaceutical
  • Xiuzheng Pharmaceutical
  • Hubei Hengan
  • TARO
  • Perrigo
  • Galderma pharm
  • Zhejiang Deyer
  • Valeant Pharma
  • Moberg

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Onychomycosis (Tinea Unguium) Drug Market by Type
  3. 1.2.1 Global Onychomycosis (Tinea Unguium) Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oral Medication
  5. 1.2.3 External Medicine
  6. 1.3 Onychomycosis (Tinea Unguium) Drug Market by Application
  7. 1.3.1 Global Onychomycosis (Tinea Unguium) Drug Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Age under 18
  9. 1.3.3 Age 18-50
  10. 1.3.4 Age above 50
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Onychomycosis (Tinea Unguium) Drug Market Dynamics
  1. 2.1 Onychomycosis (Tinea Unguium) Drug Industry Trends
  2. 2.2 Onychomycosis (Tinea Unguium) Drug Industry Drivers
  3. 2.3 Onychomycosis (Tinea Unguium) Drug Industry Opportunities and Challenges
  4. 2.4 Onychomycosis (Tinea Unguium) Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Onychomycosis (Tinea Unguium) Drug Market Perspective (2021-2032)
  2. 3.2 Global Onychomycosis (Tinea Unguium) Drug Growth Trends by Region
  3. 3.2.1 Global Onychomycosis (Tinea Unguium) Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Onychomycosis (Tinea Unguium) Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Onychomycosis (Tinea Unguium) Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Onychomycosis (Tinea Unguium) Drug Revenue by Players
  2. 4.1.1 Global Onychomycosis (Tinea Unguium) Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Onychomycosis (Tinea Unguium) Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Onychomycosis (Tinea Unguium) Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Onychomycosis (Tinea Unguium) Drug Key Players Headquarters & Area Served
  7. 4.4 Global Onychomycosis (Tinea Unguium) Drug Players, Product Type & Application
  8. 4.5 Global Onychomycosis (Tinea Unguium) Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Onychomycosis (Tinea Unguium) Drug Market CR5 and HHI
  11. 4.6.3 2025 Onychomycosis (Tinea Unguium) Drug Tier 1, Tier 2, and Tier 3
5 Onychomycosis (Tinea Unguium) Drug Market Size by Type
  1. 5.1 Global Onychomycosis (Tinea Unguium) Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Onychomycosis (Tinea Unguium) Drug Revenue by Type (2021-2032)
  3. 5.3 Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Type (2021-2032)
6 Onychomycosis (Tinea Unguium) Drug Market Size by Application
  1. 6.1 Global Onychomycosis (Tinea Unguium) Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Onychomycosis (Tinea Unguium) Drug Revenue by Application (2021-2032)
  3. 6.3 Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Pfizer
  2. 7.1.1 Pfizer Company Information
  3. 7.1.2 Pfizer Business Overview
  4. 7.1.3 Pfizer Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Pfizer Onychomycosis (Tinea Unguium) Drug Product Portfolio
  6. 7.1.5 Pfizer Recent Developments
  7. 7.2 Yangtze River
  8. 7.2.1 Yangtze River Company Information
  9. 7.2.2 Yangtze River Business Overview
  10. 7.2.3 Yangtze River Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Yangtze River Onychomycosis (Tinea Unguium) Drug Product Portfolio
  12. 7.2.5 Yangtze River Recent Developments
  13. 7.3 Torrent Pharma
  14. 7.3.1 Torrent Pharma Company Information
  15. 7.3.2 Torrent Pharma Business Overview
  16. 7.3.3 Torrent Pharma Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Torrent Pharma Onychomycosis (Tinea Unguium) Drug Product Portfolio
  18. 7.3.5 Torrent Pharma Recent Developments
  19. 7.4 J&J
  20. 7.4.1 J&J Company Information
  21. 7.4.2 J&J Business Overview
  22. 7.4.3 J&J Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 J&J Onychomycosis (Tinea Unguium) Drug Product Portfolio
  24. 7.4.5 J&J Recent Developments
  25. 7.5 Chengdu Brilliant
  26. 7.5.1 Chengdu Brilliant Company Information
  27. 7.5.2 Chengdu Brilliant Business Overview
  28. 7.5.3 Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Product Portfolio
  30. 7.5.5 Chengdu Brilliant Recent Developments
  31. 7.6 Novartis
  32. 7.6.1 Novartis Company Information
  33. 7.6.2 Novartis Business Overview
  34. 7.6.3 Novartis Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Novartis Onychomycosis (Tinea Unguium) Drug Product Portfolio
  36. 7.6.5 Novartis Recent Developments
  37. 7.7 Qilu Pharmaceutical
  38. 7.7.1 Qilu Pharmaceutical Company Information
  39. 7.7.2 Qilu Pharmaceutical Business Overview
  40. 7.7.3 Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Product Portfolio
  42. 7.7.5 Qilu Pharmaceutical Recent Developments
  43. 7.8 Xiuzheng Pharmaceutical
  44. 7.8.1 Xiuzheng Pharmaceutical Company Information
  45. 7.8.2 Xiuzheng Pharmaceutical Business Overview
  46. 7.8.3 Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Product Portfolio
  48. 7.8.5 Xiuzheng Pharmaceutical Recent Developments
  49. 7.9 Hubei Hengan
  50. 7.9.1 Hubei Hengan Company Information
  51. 7.9.2 Hubei Hengan Business Overview
  52. 7.9.3 Hubei Hengan Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Hubei Hengan Onychomycosis (Tinea Unguium) Drug Product Portfolio
  54. 7.9.5 Hubei Hengan Recent Developments
  55. 7.10 TARO
  56. 7.10.1 TARO Company Information
  57. 7.10.2 TARO Business Overview
  58. 7.10.3 TARO Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 TARO Onychomycosis (Tinea Unguium) Drug Product Portfolio
  60. 7.10.5 TARO Recent Developments
  61. 7.11 Perrigo
  62. 7.11.1 Perrigo Company Information
  63. 7.11.2 Perrigo Business Overview
  64. 7.11.3 Perrigo Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Perrigo Onychomycosis (Tinea Unguium) Drug Product Portfolio
  66. 7.11.5 Perrigo Recent Developments
  67. 7.12 Galderma pharm
  68. 7.12.1 Galderma pharm Company Information
  69. 7.12.2 Galderma pharm Business Overview
  70. 7.12.3 Galderma pharm Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Galderma pharm Onychomycosis (Tinea Unguium) Drug Product Portfolio
  72. 7.12.5 Galderma pharm Recent Developments
  73. 7.13 Zhejiang Deyer
  74. 7.13.1 Zhejiang Deyer Company Information
  75. 7.13.2 Zhejiang Deyer Business Overview
  76. 7.13.3 Zhejiang Deyer Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Zhejiang Deyer Onychomycosis (Tinea Unguium) Drug Product Portfolio
  78. 7.13.5 Zhejiang Deyer Recent Developments
  79. 7.14 Valeant Pharma
  80. 7.14.1 Valeant Pharma Company Information
  81. 7.14.2 Valeant Pharma Business Overview
  82. 7.14.3 Valeant Pharma Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Valeant Pharma Onychomycosis (Tinea Unguium) Drug Product Portfolio
  84. 7.14.5 Valeant Pharma Recent Developments
  85. 7.15 Moberg
  86. 7.15.1 Moberg Company Information
  87. 7.15.2 Moberg Business Overview
  88. 7.15.3 Moberg Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Moberg Onychomycosis (Tinea Unguium) Drug Product Portfolio
  90. 7.15.5 Moberg Recent Developments
8 North America
  1. 8.1 North America Onychomycosis (Tinea Unguium) Drug Revenue (2021-2032)
  2. 8.2 North America Onychomycosis (Tinea Unguium) Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Onychomycosis (Tinea Unguium) Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Onychomycosis (Tinea Unguium) Drug Revenue by Type (2027-2032)
  5. 8.3 North America Onychomycosis (Tinea Unguium) Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Onychomycosis (Tinea Unguium) Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Onychomycosis (Tinea Unguium) Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Onychomycosis (Tinea Unguium) Drug Revenue by Application (2027-2032)
  9. 8.5 North America Onychomycosis (Tinea Unguium) Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Onychomycosis (Tinea Unguium) Drug Revenue by Country
  11. 8.6.1 North America Onychomycosis (Tinea Unguium) Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Onychomycosis (Tinea Unguium) Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Onychomycosis (Tinea Unguium) Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Onychomycosis (Tinea Unguium) Drug Revenue (2021-2032)
  2. 9.2 Europe Onychomycosis (Tinea Unguium) Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Onychomycosis (Tinea Unguium) Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Onychomycosis (Tinea Unguium) Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Onychomycosis (Tinea Unguium) Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Onychomycosis (Tinea Unguium) Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Onychomycosis (Tinea Unguium) Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Onychomycosis (Tinea Unguium) Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Onychomycosis (Tinea Unguium) Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Onychomycosis (Tinea Unguium) Drug Revenue by Country
  11. 9.6.1 Europe Onychomycosis (Tinea Unguium) Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Onychomycosis (Tinea Unguium) Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Onychomycosis (Tinea Unguium) Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Onychomycosis (Tinea Unguium) Drug Revenue (2021-2032)
  2. 10.2 China Onychomycosis (Tinea Unguium) Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Onychomycosis (Tinea Unguium) Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Onychomycosis (Tinea Unguium) Drug Revenue by Type (2027-2032)
  5. 10.3 China Onychomycosis (Tinea Unguium) Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Onychomycosis (Tinea Unguium) Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Onychomycosis (Tinea Unguium) Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Onychomycosis (Tinea Unguium) Drug Revenue by Application (2027-2032)
  9. 10.5 China Onychomycosis (Tinea Unguium) Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Onychomycosis (Tinea Unguium) Drug Revenue (2021-2032)
  2. 11.2 Asia Onychomycosis (Tinea Unguium) Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Onychomycosis (Tinea Unguium) Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Onychomycosis (Tinea Unguium) Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Onychomycosis (Tinea Unguium) Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Onychomycosis (Tinea Unguium) Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Onychomycosis (Tinea Unguium) Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Onychomycosis (Tinea Unguium) Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Onychomycosis (Tinea Unguium) Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Onychomycosis (Tinea Unguium) Drug Revenue by Country
  11. 11.6.1 Asia Onychomycosis (Tinea Unguium) Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Onychomycosis (Tinea Unguium) Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Onychomycosis (Tinea Unguium) Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Onychomycosis (Tinea Unguium) Drug Revenue (2021-2032)
  2. 12.2 SAMEA Onychomycosis (Tinea Unguium) Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Onychomycosis (Tinea Unguium) Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Onychomycosis (Tinea Unguium) Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Onychomycosis (Tinea Unguium) Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Onychomycosis (Tinea Unguium) Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Onychomycosis (Tinea Unguium) Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Onychomycosis (Tinea Unguium) Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Onychomycosis (Tinea Unguium) Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Onychomycosis (Tinea Unguium) Drug Revenue by Country
  11. 12.6.1 SAMEA Onychomycosis (Tinea Unguium) Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Onychomycosis (Tinea Unguium) Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Onychomycosis (Tinea Unguium) Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst